Biotech · Private company
Theranexus
Track this companyFree. Adds Theranexus to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- THN102 Dosage APhase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- THN102 Dosage BPhase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- THN102 Dosage CPhase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Study With Batten-1 (Miglustat Liquid Formulation) to Treat Ceroid Lipofuscinosis Neuronal 3 (CLN3) DiseasePHASE3 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07882290 · fetched Nov 12, 2026
- An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) DiseasePHASE1_PHASE2 · COMPLETED · started Mar 10, 2022ClinicalTrials.gov NCT05174039 · fetched Nov 12, 2026
- Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime SleepinessPHASE2 · COMPLETED · started Jul 12, 2018ClinicalTrials.gov NCT03624920 · fetched Nov 12, 2026